<DOC>
	<DOCNO>NCT01432106</DOCNO>
	<brief_summary>Study purpose : African Americans hypertension marker metabolic syndrome ( small elevation blood glucose , triglyceride weight ) high risk cardiovascular ( heart blood vessel ) problem . There circulate factor call angiotensin II increase risk may important African Americans 20 time great risk lose kidney function require dialysis . Research Investigators , include University Michigan , find one drug ( Ramipril ) block angiotensin II effect significantly improve kidney function African Americans . The purpose The SAAVE Study determine whether combination two new blocker ( Valsartan Aliskiren ) angiotensin II , well able low blood pressure , also improve risk factor cardiovascular problem provide great protection heart kidney .</brief_summary>
	<brief_title>The Study Novel Dual Renin Angiotensin Aldosterone System ( RAAS ) Blockade ; Valsartan/Aliskiren African American Patients With Hypertension Metabolic Syndrome</brief_title>
	<detailed_description>The specific hypothesis proposal combination Valsartan/Aliskiren provide incremental reduction blood pressure compare traditional blockade Renin Angiotensin Aldosterone System ( RAAS ) ramipril . As exploratory analysis , propose blood pressure effect associate suppress plasma aldosterone level , preserve availability nitric oxide , prevent development insulin resistance . Other variables interest include change baseline adiponectin , Procollagen 1 3 , osteopontin , cystatin C , serum K+ . In nested cohort determine impact novel dual RAAS blockade leave ventricular remodel . Should hypotheses proven correct novel dual RAAS blockade effective ramipril reduce blood pressure , plasma aldosterone , preserve availability nitric oxide , reflect increase asymmetric dimethly arginine ( ADMA ) level , improve cardiovascular remodeling , would important implication long term prevention target organ damage cardiovascular event high risk ethnic group .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . African American men woman 18 80 year age . 2 . Appropriate therapy high blood pressure consist 2 antihypertensive . 3 . Patients least one marker Metabolic Syndrome evidence : HDL cholesterol &lt; 35mg/dl ( men ) ; &lt; 45 mg/dl ( woman ) Triglycerides &gt; 200mg/dl Fasting Glucose &gt; 100mg/dl Waist Circumference : Men &gt; 40 inch ( 102cm ) ; Women &gt; 35 ( 88cm ) 4 . Recent copy EKG . 5 . Women able become pregnant must use reliable contraception ( e.g . hormonal contraception doublebarrier method ) throughout study one week end study . Postmenopausal surgically sterile woman . 1 . Uncontrolled hypertension . 2 . Organ transplant . 3 . Hypersensitivity study medication 4 . Systolic pressure 170 high Diastolic pressure 110 high . 5 . Cardiovascular event within last 6 month Stroke , Heart Attack , Stent , Hospitalization severe Heart Failure . 6 . Serum potassium great 5.0 7 . Heart block without pacemaker , continue arrhythmia valvular heart disease . 8 . Blocked renal artery . 9 . Patients severe renal impairment ( creatinine 1.7 mg/dl woman 2.0 mg/dl men estimate GFR &lt; 30 mL/min ) history dialysis , nephritic syndrome , renovascular hypertension . 10 . Any condition may alter medication absorption . 11 . Any condition may place patient high risk participate study jeopardize evaluation efficacy safety . 12 . Use investigational study medication within 30 day enrollment 13 . Persons unwilling unable take regular medication comply study protocol . 14 . Pregnant nursing ( lactate ) woman , woman childbearing potential ( defined woman physiologically capable become pregnant ) use reliable method contraception : surgical sterilization , bilateral tubal ligation , hormonal contraception , implantable oral ) double barrier method accept local regulatory authority ethic committee . Reliable contraception maintain throughout study 7 day study drug discontinuation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>African American</keyword>
</DOC>